Clinical trial NCT05483933: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers
Official title: An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Platinum-resistant Ovarian Cancer
Fallopian Tube Cancer
Epithelial Ovarian Cancer
Ovarian Cancer
Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma
Primary Peritoneal Carcinoma
Keywords: Platinum-resistant
Ovarian
Peritoneal
High grade serous EOC
primary peritoneal cancer
Fallopian
Combination
Mirvetuximab Soravtansine
SL-172154
SIRPα-Fc-CD40L
Pegylated Liposomal Doxorubicin
Lead sponsor: Shattuck Labs, Inc.
Sponsor class: INDUSTRY
First posted: 2022-08-02
Enrollment: 86
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in this study in two phases: dose escalation and dose expansion.

Detailed description: Study SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate the safety, pharmacokinetics, pharmacodynamic effects, and preliminary anti-tumor activity of SL-172154 administered in combination with either PLD or MIRV in subjects with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. Patients will be appropriate for combination therapy for their next line of therapy. For the SL-172154 + MIRV cohort, patients' tumors must be positive (defined as PS2+ ≥ 25%) for folate receptor alpha (FRα) as defined by the Ventana FOLR1 (Folate Receptor 1/Folate Receptor Alpha) Assay.

The first portion of the study will evaluate the safety of increasing dose levels of SL-172154 in combination with either PLD or MIRV and establish a combination dose for both regimens to be further evaluated in two dose expansion cohorts. The study will consist of a 21-day screening period, a study treatment period until at least one of the study treatment discontinuation criteria is met, and a study follow-up period.

Eligibility criteria: Inclusion Criteria:

1. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations.
2. Age ≥18 years
3. \[PLD Cohort\] Subject has a histologically confirmed diagnosis of high grade epithelial ovarian cancer, including primary peritoneal cancer or fallopian tube cancer. Non-epithelial tumors and ovarian tumors with low malignant potential are excluded.
4. \[PLD Cohort\] Subject must have platinum-resistant disease, defined as radiologic disease progression within 180 days (6 months) following the last administered dose of platinum therapy. Subjects who are primary platinum-refractory, defined by progressing during or within 1 month of upfront platinum therapy, are excluded.
5. \[PLD Cohort\] Subjects may have received any number of prior lines of therapy for epithelial ovarian cancer; however, they may not have received more than 1 prior line of systemic anticancer therapy for platinum-resistant disease.
6. \[MIRV Cohort\] Subject has a histologically confirmed diagnosis of high grade serous epithelial ovarian cancer, including primary peritoneal cancer or fallopian tube cancer. Non-epithelial tumors and ovarian tumors with low malignant potential are excluded.
7. \[MIRV Cohort\] Subject must have platinum-resistant disease as defined by:

   * Subjects who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response (complete response/remission \[CR\] or partial response/remission \[PR\]) and then progressed between \>3 months and ≤6 months after the date of the last dose of platinum.
   * Subjects who have received 2 or 3 lines of platinum therapy must have progressed on or within 6 months after the date of the last dose of platinum.
   * Subjects who are platinum refractory during front-line treatment are excluded \[primary platinum-refractory disease, defined as disease that did not respond to (CR or PR) or has progressed within 3 months of the last dose of first-line platinum-containing chemotherapy\]
8. \[MIRV Cohort\] Subjects must have received at least 1 but no more than 3 prior systemic lines of anticancer therapy.
9. \[MIRV Cohort\] Willing to provide an archival tumor tissue block or slides or undergo procedure to obtain new biopsy using a low-risk, medically routine procedure for IHC confirmation of FRα positivity.
10. \[MIRV Cohort\] Subject's tumor must be positive for FRα expression (defined as PS2+ ≥ 25% by the Ventana FOLR1 Assay).
11. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
12. Measurable disease by RECIST v1.1 using radiologic assessment.
13. Adequate organ and hematologic function
14. Subjects must have stabilized or recovered (Grade 1 or baseline) from all prior anti-cancer therapy-related toxicities.
15. \[MIRV Cohort, Dose Expansion only\] Willing to consent to 1 mandatory pre-treatment and 1 on-treatment tumor biopsy, unless there is excessive risk from the procedure as determined by the investigator

Exclusion Criteria:

1. Prior treatment with a signal-regulatory protein alpha (SIRPα) targeting agent, anti-CD47 agent or CD40 agonist.
2. \[PLD Cohort\] Prior treatment with doxorubicin or PLD
3. \[MIRV Cohort\] Prior treatment with MIRV or another FRα-targeting agent
4. Any anti-cancer therapy within the time intervals specified per protocol.
5. Concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment is prohibited.
6. Receipt of live attenuated vaccine (including live attenuated vaccines for COVID-19) within 28 days of the first dose of study treatment.
7. Current or prior use of systemic immunosuppressive medication within 7 days prior to first dose of study treatment.
8. \[MIRV Cohort\] Requires use of folate-containing supplements (e.g., folate deficiency)
9. Active or documented history of autoimmune disease that has required treatment with a disease modifying agent or immunosuppressive therapy in the past two years, history of multiple sclerosis (MS) or other demyelinating disease and/or Lambert-Eaton syndrome (paraneoplastic syndrome). Exceptions include controlled Type I diabetes, vitiligo, alopecia areata or hypo/hyperthyroidism.
10. Ongoing or active infection (e.g., no systemic antimicrobial therapy for treatment of infection within 5 days of D1 of study treatment).
11. Known severe hypersensitivity to the active drug substance or to any of the excipients for the agents to be administered or known hypersensitivity to Chinese hamster ovary cell products.
12. Severe gastrointestinal conditions.
13. Clinically significant or uncontrolled cardiovascular disease
14. \[MIRV Cohort\] History of cirrhotic liver disease (Child-Pugh Class B or C)
15. \[MIRV Cohort\] Active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and/or monocular vision.
16. Previous clinical diagnosis of noninfectious interstitial lung disease (ILD), including noninfectious pneumonia.
17. Untreated central nervous system or leptomeningeal metastases.
18. Another malignancy that requires active therapy and that, in the opinion of the investigator and Sponsor, would interfere with monitoring of radiologic assessments of response to the study treatment.
19. Has undergone allogeneic stem cell transplantation or organ transplantation.
20. Known history or positive test for human immunodeficiency virus (HIV), or positive test for hepatitis B (positive for hepatitis B surface antigen \[HBsAg\]) or hepatitis C virus (\[HCV\]

Primary outcomes:
measure: Evaluate safety and tolerability of SL-172154 when administered with PLD
timeFrame: first dose up to 3 years
measure: Evaluate safety and tolerability of SL-172154 when administered with MIRV
timeFrame: first dose up to 3 years
measure: Establish the recommended Phase 2 dose (RP2D) for SL-172154 when administered with PLD
timeFrame: first dose up to 1 year
measure: Establish the recommended Phase 2 dose (RP2D) for SL-172154 when administered with MIRV
timeFrame: first dose up to 1 year
Secondary outcomes:
measure: To assess preliminary evidence of anti-tumor activity of SL-172154 when administered with PLD
timeFrame: first dose up to 3 years
measure: To assess preliminary evidence of anti-tumor activity of SL-172154 when administered with MIRV
timeFrame: first dose up to 3 years
measure: Immunogenicity to SL-172154
timeFrame: first dose up to 3 years
measure: Immunogenicity to MIRV
timeFrame: first dose up to 3 years
measure: Maximum serum concentration (Cmax) of SL-172154
timeFrame: first dose up to 3 years
measure: Maximum serum concentration (Cmax) of MIRV
timeFrame: first dose up to 3 years
measure: Maximum serum concentration (Cmax) of Total Antibody
timeFrame: first dose up to 3 years
measure: Maximum serum concentration (Cmax) of DM4 Payload
timeFrame: first dose up to 3 years
measure: Maximum serum concentration (Cmax) of S-Methyl DM4 Payload
timeFrame: first dose up to 3 years
measure: Area under the serum concentration-time curve (AUC) of SL-172154
timeFrame: first dose up to 3 years
measure: Area under the serum concentration-time curve (AUC) of MIRV
timeFrame: first dose up to 3 years
measure: Area under the serum concentration-time curve (AUC) of Total Antibody
timeFrame: first dose up to 3 years
measure: Area under the serum concentration-time curve (AUC) of DM4 Payload
timeFrame: first dose up to 3 years
measure: Area under the serum concentration-time curve (AUC) of S-Methyl DM4 Payload
timeFrame: first dose up to 3 years
measure: Terminal elimination half-life (t1/2) of SL-172154
timeFrame: first dose up to 3 years
measure: Terminal elimination half-life (t1/2) of MIRV
timeFrame: first dose up to 3 years
measure: Terminal elimination half-life (t1/2) of Total Antibody
timeFrame: first dose up to 3 years
measure: Terminal elimination half-life (t1/2) of DM4 Payload
timeFrame: first dose up to 3 years
measure: Terminal elimination half-life (t1/2) of S-Methyl DM4 Payload
timeFrame: first dose up to 3 years
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: University of Arkansas for Medical sciences
state: Arkansas
city: Duarte
country: United States
facility: City of Hope
state: California
city: Chicago
country: United States
facility: Robert H.Lurie ComprehensiveCancer Center, Northwestern University
state: Illinois
city: Grand Rapids
country: United States
facility: START Midwest
state: Michigan
city: Oklahoma City
country: United States
facility: Stephenson Cancer Center, OU Health/ Sarah Cannon Research Institute
state: Oklahoma
city: Vancouver
country: Canada
facility: BC Cancer Center
state: British Columbia
city: Toronto
country: Canada
facility: University health Network (UHN)-University of Toronto
state: Ontario
city: Montréal
country: Canada
facility: McGill University Health Care
state: Quebec
city: Badalona
country: Spain
facility: Hospital Universitari Germans Trias i Pujol
state: Barcelona
city: Barcelona
country: Spain
facility: Hospital Clinic de Barcelona Servicio de Oncología, Esc. 2, Planta 5 dcha
state: Catalunya
city: Barcelona
country: Spain
facility: Hospital Universitario Quirón-Dexeus Servicio de Oncologia Médica
city: Girona
country: Spain
facility: Hospital Universitario Dr. Josep Trueta - ICO de Girona, Servicio de Oncología Av. Francia s/n
city: Madrid
country: Spain
facility: Hospital Universitari Vall D Hebron
city: Madrid
country: Spain
facility: Hospital Universitario Fundacion Jimenez Diaz START Madrid-FJD- Unidad de Ensayos Fase I
city: Murcia
country: Spain
facility: Hospital Universitario Virgen de la Arrixaca. Servicio de Oncología Ctra. Madrid-Cartagena, s/n
city: Preston
country: United Kingdom
facility: Lancashire Teaching Hospitals NHS Foundation Trust
state: Lancashire
city: London
country: United Kingdom
facility: Guy's & St Thomas' NHS Foundation Trust
city: London
country: United Kingdom
facility: The Royal Marsden NHS Foundation Trust
city: London
country: United Kingdom
facility: University College London Hospitals NHS Foundation Trust
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust
city: Sutton
country: United Kingdom
facility: The Royal Marsden NHS Foundation Trust
Study officials:
References: